CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Drugs (New Approvals & NDA)
High ImpactOriginal article

CDER proposes to withdraw approval of TAVNEOS

RegulatoryrejectedTAVNEOSNegative
AI Analysis

Summary

The FDA's Center for Drug Evaluation and Research (CDER) has proposed to withdraw approval of TAVNEOS. This represents a significant regulatory setback for the drug's manufacturer.

Outcome Details

CDER proposes to withdraw approval

Importance:9/10
Sentiment:
-0.95
regulatory_actiondrug_withdrawalFDA

Read the original article

Published by FDA Drugs (New Approvals & NDA) on July 13, 2026 10:09 AM

Read Original